Search
AS1409
go.drugbank.com/drugs/DB05182InvestigationalThe other is an antibody that targets tumours. It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma.
Resveratrol
go.drugbank.com/drugs/DB02709InvestigationalIt is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. … In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation.
Categories: Compounds used in a research, industrial, or household settingSynonyms: (E)-resveratrol, (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediolMethyl undecenoyl leucinate
go.drugbank.com/drugs/DB11272ApprovedMethyl undecenoyl leucinate is an active ingredient in whitening creams. … It is an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of various melanogenic genes.
RI 624
go.drugbank.com/drugs/DB05892ExperimentalRI 624 is being developed by Rinat and is currently in Phase I clinical trials.
Ixabepilone
go.drugbank.com/drugs/DB04845ApprovedInvestigationalIxabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. … It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer.
NGD-4715
go.drugbank.com/drugs/DB06027ExperimentalNGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.
Midecamycin
go.drugbank.com/drugs/DB13456InvestigationalIn this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar.
Methazolamide
go.drugbank.com/drugs/DB00703ApprovedA carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
MF101
go.drugbank.com/drugs/DB05052InvestigationalMF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women. … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation
ATN-161
go.drugbank.com/drugs/DB05491InvestigationalIt inhibits the migration and adhesion of particular integrins on activated endothelial cells that play a critical role in tumor angiogenesis. … This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective in single therapy as well as combination therapy.